Literature DB >> 14607338

Lack of prognostic significance of survivin, survivin-deltaEx3, survivin-2B, galectin-3, bag-1, bax-alpha and MRP-1 mRNAs in breast cancer.

Lorraine O'Driscoll1, Rasha Linehan, Susan M Kennedy, Deirdre Cronin, Rachel Purcell, Sharon Glynn, Enda W McDermott, Arnold D Hill, Niall J O'Higgins, Michael Parkinson, Martin Clynes.   

Abstract

The expression of transcripts for anti-apoptotic (survivin, survivin-deltaEx3, survivin-2B, galectin-3, bag-1 and bcl-2) and pro-apoptotic (bax-alpha) genes, and for multiple drug resistance related protein-1 (MRP-1) gene were investigated, using RT-PCR, in 106 breast tumour biopsies. Normal breast tissue was also analysed for comparative purposes. Overall, survivin, survivin-deltaEx3, survivin-2B, bcl-2, bag-1, galectin-3, bax-alpha and MRP-1 mRNAs were detected in 68, 54.7, 9.4, 78.4, 80.9, 98.9, 97.8 and 72.8%, respectively, of tumour specimens. Uniquely among the mRNAs analysed, the expression of bcl-2 correlated significantly with disease outcome, with bcl-2 expression indicative of favourable outcome in terms of both relapse-free survival and overall survival. This suggests that bcl-2 mRNA expression may be a key prognostic marker for breast cancer and that routine analysis of expression of this transcript should be considered. The results from this study suggest, however, that the expression of survivin, survivin-deltaEx3, survivin-2B, bag-1, galectin-3, bax-alpha and MRP-1 mRNAs cannot be considered as prognostic indicators of disease outcome for patients with breast cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14607338     DOI: 10.1016/s0304-3835(03)00518-4

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  21 in total

1.  Reproductive and sex hormonal factors and oesophageal and gastric junction adenocarcinoma: a pooled analysis.

Authors:  Deirdre P Cronin-Fenton; Liam J Murray; David C Whiteman; Chris Cardwell; Penelope M Webb; Susan J Jordan; Douglas A Corley; Linda Sharp; Jesper Lagergren
Journal:  Eur J Cancer       Date:  2010-04-22       Impact factor: 9.162

2.  Reciprocal expression of survivin and SMAC/DIABLO in primary breast cancer.

Authors:  A Mansour; M Nabil; R Ali-Labib; H Said; F Annos
Journal:  Med Oncol       Date:  2011-12-08       Impact factor: 3.064

3.  Significance of survivin and Bcl-2 homologous antagonist/killer mRNA in detection of bone metastasis in patients with breast cancer.

Authors:  Samir F Zohny; Mohamed El-Shinawi
Journal:  Med Oncol       Date:  2010-10-27       Impact factor: 3.064

4.  Regulation of galectin-3 function in mucosal fibroblasts: potential role in mucosal inflammation.

Authors:  E Lippert; M Gunckel; J Brenmoehl; F Bataille; W Falk; J Scholmerich; F Obermeier; G Rogler
Journal:  Clin Exp Immunol       Date:  2008-03-10       Impact factor: 4.330

5.  Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy.

Authors:  Lee B Rivera; David Meyronet; Valérie Hervieu; Mitchell J Frederick; Emily Bergsland; Gabriele Bergers
Journal:  Cell Rep       Date:  2015-04-16       Impact factor: 9.423

6.  The role of survivin in diagnosis, prognosis and treatment of breast cancer.

Authors:  Yong-Gang Lv; Fang Yu; Qing Yao; Jiang-Hao Chen; Ling Wang
Journal:  J Thorac Dis       Date:  2010-06       Impact factor: 2.895

7.  Induction of HLA-DP4-restricted anti-survivin Th1 and Th2 responses using an artificial antigen-presenting cell.

Authors:  Makito Tanaka; Marcus O Butler; Sascha Ansén; Osamu Imataki; Alla Berezovskaya; Lee M Nadler; Naoto Hirano
Journal:  Clin Cancer Res       Date:  2011-06-24       Impact factor: 12.531

8.  Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer.

Authors:  Donal J Brennan; Elton Rexhepaj; Sallyann L O'Brien; Elaine McSherry; Darran P O'Connor; Ailís Fagan; Aedín C Culhane; Desmond G Higgins; Karin Jirstrom; Robert C Millikan; Goran Landberg; Michael J Duffy; Stephen M Hewitt; William M Gallagher
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

9.  Expression of survivin does not appear to influence breast cancer recurrence risk.

Authors:  Lindsay J Collin; Deirdre P Cronin-Fenton; Thomas P Ahern; Kristina B Christensen; Per Damkier; Stephen Hamilton-Dutoit; Anders Kjaersgaard; Kristina L Lauridsen; Rami Yacoub; Peer Christiansen; Henrik Toft Sørensen; Timothy L Lash
Journal:  Acta Oncol       Date:  2018-10-23       Impact factor: 4.089

10.  Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer.

Authors:  Elton Rexhepaj; Karin Jirstrom; Darran P O'Connor; Sallyann L O'Brien; Goran Landberg; Michael J Duffy; Donal J Brennan; William M Gallagher
Journal:  BMC Cancer       Date:  2010-11-23       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.